Prescription drug · NDA
Varubi (Rolapitant) NDC 87628-101
Rolapitant hydrochloride 90 mg/1 · Tablet · Oral · Luria Therapeutics LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 87628-101-02 | 87628010102 | 2 TABLET in 1 BLISTER PACK (87628-101-02)Marketed from Sep 8, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Varubi
- Generic name (nonproprietary)
- rolapitant
- Active ingredients
- Rolapitant hydrochloride — 90 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Luria Therapeutics LLCNDC labeler code 87628
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 206500
- Marketing start
- Listing expires
- Other FDA classes
- Breast Cancer Resistance Protein Inhibitors (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
- Identifiers
- Product ID 87628-101_25c6e790-1e90-4901-b85b-f24d2c8c2b04SPL ID 25c6e790-1e90-4901-b85b-f24d2c8c2b04SPL set ID 8670c3cf-82d9-466d-be49-de33d8c8742bRxCUI 1665503, 1673373UNII 57O5S1QSAQ
- Pharmacologic class
- Substance P/Neurokinin-1 Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N487628010102followed by a unit qualifier and the quantityPackage 87628-0101-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 87628-101
- What is NDC 87628-101?
- 87628-101 is the product NDC for Varubi (rolapitant), Rolapitant hydrochloride 90 mg/1 tablet, listed with the FDA by Luria Therapeutics LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Varubi (Rolapitant).
- What is the active ingredient?
- Rolapitant hydrochloride.
- Who is the labeler?
- Luria Therapeutics LLC, NDC labeler code 87628. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Varubi?
- 1 other product NDC are listed under this name. See all Varubi NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Varubi products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Varubirolapitant | Rolapitant hydrochloride 90 mg/1 | TabletOral | TerSera Therapeutics LLC | 70720-101 | 70720-0101-02 |
Other NDCs under NDA 206500
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Varubirolapitant | Rolapitant hydrochloride 90 mg/1 | TabletOral | TerSera Therapeutics LLC | 70720-101 |